Last $5.64 USD
Change Today +0.13 / 2.36%
Volume 15.9K
HBIO On Other Exchanges
Symbol
Exchange
Frankfurt
As of 12:30 PM 03/6/15 All times are local (Market data is delayed by at least 15 minutes).

harvard bioscience inc (HBIO) Snapshot

Open
$5.46
Previous Close
$5.51
Day High
$5.66
Day Low
$5.46
52 Week High
12/31/14 - $5.93
52 Week Low
06/25/14 - $3.68
Market Cap
182.8M
Average Volume 10 Days
101.1K
EPS TTM
$0.12
Shares Outstanding
32.4M
EX-Date
--
P/E TM
45.8x
Dividend
--
Dividend Yield
--
Current Stock Chart for HARVARD BIOSCIENCE INC (HBIO)

Related News

No related news articles were found.

harvard bioscience inc (HBIO) Related Businessweek News

No Related Businessweek News Found

harvard bioscience inc (HBIO) Details

Harvard Bioscience, Inc. develops, manufactures, distributes, and markets scientific instruments, systems, and lab consumables used in life science research. The company offers syringe pumps and peristaltic pumps primarily under the Harvard Apparatus and KD Scientific brands, as well as component pumping modules; and lab equipment and supplies comprising pipettes and pipette tips, gloves, gel electrophoresis and autoradiography products, thermal cycler accessories and reagents, general lab equipment and consumables, and tissue culture products primarily under the Denville Scientific, Hoefer, and Scie-Plas brands. It also provides molecular analysis products, such as spectrophotometers under the UltroSpec, NovaSpec, Libra, and BioDrop brands; microplate readers under the Asys Hitech and Anthos Labtec brands; and amino acid analyzers under the Biochrom brand. In addition, the company offers electroporation and electrofusion products comprising systems and generators, electrodes, and accessories under the Harvard Apparatus BTX brand; and cell electrophysiology products, such as equipment for patch clamps, amplifiers, bilayer workstations, temperature controllers, chambers, and accessories under the Warner Instrument brand. Further, it provides physiology products, which include a range of instruments and accessories for tissue, organ, and animal based lab research, ranging from surgical products, infusion systems, microdialysis instruments, behavior research products, isolated perfused organ and tissue bath systems, and research-based regenerative medicine products under the Harvard Apparatus, CMA Microdialysis, Panlab, Coulbourn, Hugo-Sachs, and InBreath Bioreactor brands. It markets its products to research scientists at universities, hospitals, government laboratories, and pharmaceutical and biotechnology companies through catalogs, distributors, direct sales force, and its Websites. The company was founded in 1901 and is headquartered in Holliston, Massachusetts.

harvard bioscience inc (HBIO) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $271.8K
Co-Founder and Director
Total Annual Compensation: $420.6K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $54.8K
Vice President of Strategic Marketing and Bus...
Total Annual Compensation: $64.5K
Vice President of Global Sales
Total Annual Compensation: $34.0K
Compensation as of Fiscal Year 2013.

harvard bioscience inc (HBIO) Key Developments

Harvard Bioscience Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014; Provides Earning Guidance for the Year 2015

Harvard Bioscience Inc. reported unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2014. Revenues for the three months ended December 31, 2014 were $30.4 million, an increase of approximately 9.0%, or $2.5 million compared to revenues of $27.9 million for the three months ended December 31, 2013. Income from continuing operations, as measured under U.S. generally accepted accounting principles, was a loss of $19,000, or $0.00 per diluted share compared to a loss of $255,000, or $0.01 per diluted share, for the same quarter in 2013. Overall, the favorable year-to-year quarterly GAAP earnings comparison was due primarily to an increase in revenues and gross profit, and lower operating expenses, partially offset by acquisition costs and higher income tax expense. Income from continuing operations, on a non-GAAP basis, increased 97% to $3.3 million for the fourth quarter 2014, and increased 100% to $0.10 per diluted share, compared to $1.7 million, and $0.05 per diluted share, for the three months ended December 31, 2013. Operating profit was $2.12 million against operating loss of $0.949 million a year ago. Non-GAAP adjusted operating income was $4.70 million against $2.70 million a year ago. Revenues for the year ended December 31, 2014 were $108.7 million, an increase of approximately 3.3%, or $3.5 million compared to revenues of $105.2 million for the year ended December 31, 2013. Income from continuing operations, as measured under GAAP, was $2.4 million, or $0.07 per diluted share, for the year ended December 31, 2014 compared to $0.7 million, or $0.02 per diluted share, for the same period in 2013. Income from continuing operations, on a non-GAAP basis, increased 26% to $8.9 million for the year ended December 31, 2014, and increased 21% to $0.27 per diluted share, compared to $7.1 million, and $0.22 per diluted share, for the year ended December 31, 2013. Operating profit was $6.61 million against $1.53 million a year ago. Net cash provided by operating activities was $4.35 million against 4.06 million a year ago. Acquisitions, net of cash acquired were $12.65 million compared to $1.6 million in 2013. The increase in capital expenditures this year is due to investments in the company's infrastructure and ERP system as well as buildouts related to the consolidation of its U.K. manufacturing facility with the company's Holliston, Massachusetts facility. Non-GAAP adjusted operating income was $13.26 million against $10.92 million a year ago. The company is providing financial guidance for the full year 2015. The guidance includes the expected negative impact of currency translation due to the strengthening of the U.S. dollar, expected costs of relocation and consolidation of certain facilities, and contributions from its recent acquisitions. The company expects revenues to be approximately $114 million to $116 million. Included in this guidance is the company's expectation that currency translation will lower revenues by between $6 million and $7 million, based on current foreign currency exchange rates. On a constant currency basis, the company expects revenues to be approximately $120 million to $123 million, or a 10% to 13% increase compared to 2014 revenues. The company expects to report full-year 2015 non-GAAP earnings per share of $0.27 to $0.28, based upon its forecasted weighted shares outstanding of 34.5 million. This translates to GAAP diluted earnings per share of approximately $0.16 to $0.17. Included in this guidance is the Company's expectation that currency translation will lower non-GAAP EPS by approximately $0.02 per diluted share. On a constant currency basis, the company expects non-GAAP EPS to be approximately $0.29 to $0.30 per diluted share, or a 7% to 11% increase compared to 2014 non-GAAP EPS. The company continues to forecast its effective tax rate in the range of 28% to 30%.

Harvard Bioscience Seeks Acquisitions

Harvard Bioscience Inc. (NasdaqGM:HBIO) is looking for acquisitions. Jeffrey Duchemin, President and Chief Executive Officer of Harvard Bioscience, states, "Acquisitions will continue to be an integral part of our growth strategy. Our acquisition pipeline is full and we will continue to strategically approach business development opportunities that align with our business strategy and core competencies."

Harvard Bioscience, Inc. Appoints Ryan Atienza to Vice President of Sales at its Denville Scientific

Harvard Bioscience Inc. has appointed Ryan Atienza to Vice President of Sales, a newly created position, at its Denville Scientific subsidiary, effective February 16. Mr. Atienza will be a member of the executive leadership team responsible for North American sales. Atienza brings more than a decade of experience working for healthcare and global life sciences companies, including selling life science consumables, instruments and equipment both direct and via distributors. Prior to joining Harvard Bioscience, he served as Manager, Business Development with American Express - Healthcare Solutions.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HBIO:US $5.64 USD +0.13

HBIO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Becton Dickinson and Co $145.53 USD -3.97
Bio-Rad Laboratories Inc $133.50 USD -0.74
Danaher Corp $85.17 USD -1.17
PerkinElmer Inc $46.77 USD -0.51
Thermo Fisher Scientific Inc $129.19 USD -2.27
View Industry Companies
 

Industry Analysis

HBIO

Industry Average

Valuation HBIO Industry Range
Price/Earnings 79.2x
Price/Sales 1.7x
Price/Book 1.9x
Price/Cash Flow 36.9x
TEV/Sales 1.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HARVARD BIOSCIENCE INC, please visit www.harvardbioscience.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.